Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Germain

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, A M Scott, C R Divgi, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft modelsC E Gidding, G S Germain, M B Dilling, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancerS Welt, A M Scott, C R Divgi, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft modelsC E Gidding, G S Germain, M B Dilling, et al.
Cancer Research|October 20, 2004
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceClinton F Stewart, Markos Leggas, John D Schuetz, et al.
Pageof 9